Skylar Jeremias

Topical delgocitinib in chronic hand eczema improves clearance and itch fast, with placebo-like safety.

A multidisciplinary Philadelphia roundtable surfaced the structural barriers that keep people with AD from reaching effective therapy.

Structured CHE diagnosis improves outcomes: a multicenter CRF clarifies causes for most patients with chronic hand eczema, addressing diagnosis challenges and guiding targeted care.

New formulations make topical retinoids for acne vulgaris and scarring more tolerable and effective, with promising data for trifarotene, tretinoin combinations, and retinols for acne.

Canadian dermatologists propose treat-to-target benchmarks for chronic hand eczema, pairing IGA-CHE and itch scores to guide therapy and follow-up.

Spanish dermatology consensus guides alopecia areata treatment escalation, highlighting JAK inhibitors, SALT-based staging, special-population care, and essential screening requirements.

The FDA's first new sunscreen ingredient approved in nearly 3 decades is set to reshape the US market. Here is what dermatologists need to know.

Dermatomyositis flares often match objective disease activity, with rash, weakness and fatigue as key signals; most flares don’t predict cancer.

New evidence links oxidative stress to vitiligo autoimmunity, highlighting antioxidant plus phototherapy or JAK combinations for better repigmentation.

A review finds diet, micronutrients, aerobic exercise, and mental health screening complement psoriasis treatment, lowering severity and comorbidity risk.

Alopecia areata shapes how people work, learn, and see themselves, a new occupational review finds, with barriers reaching far beyond hair loss.

GLP-1 medications in psoriasis show skin and inflammation gains beyond weight loss; early data in psoriatic arthritis lag as trials ramp up.

Psoriasis may share a tryptophan-driven metabolic pathway behind depression, arthritis, and metabolic syndrome.

New review guides hair loss care for transgender and gender-diverse patients, detailing how androgenic alopecia interacts with hormones and key therapies.

Three-year trial data show baricitinib sustains and deepens hair, eyebrow, and eyelash regrowth in severe alopecia areata, with stable long-term safety.

During a White House briefing, Mehmet Oz, MD, discussed the expansion of Trump Rx and crackdowns on duplicate ACA enrollment and fraudulent hospice programs.

Everyday skincare may expose you to microplastics and plastic-linked chemicals tied to skin disease and hormone disruption; dermatologists urge safer products and packaging.

The update makes biologics first-line treatment, adds comorbidity management guidance, and aligns practice with evolving European guidelines for psoriasis.

Systematic review finds SGLT2 inhibitors and newer CKD drugs boost QALYs and often save costs by delaying dialysis and transplant.

New US chronic hand eczema guidance closes diagnostic gaps and spotlights emerging therapies like delgocitinib to cut itch, pain, and work disruption.

Cancer survivors face lasting skin, hair, and nail reactions; dermatology follow-up and treatments can restore appearance, improve quality of life, and monitor risks.

Meta-analysis finds alopecia areata links to lower melanoma odds and no added skin cancer risk despite ultraviolet-exposed scalp, informing Janus kinase inhibitor safety.

Study finds endometriosis severity plateaus after 30, but surgery risk and complexity climb in older women as fibrosis and adhesions build.

Phenotype-based care improves childhood obesity diagnosis and treatment, including obesity types, hypothalamic obesity, drugs, and surgery.

The scoping review shows menopause and multiple sclerosis (MS) shift from fewer relapses to higher symptom burden, highlighting care gaps for older women with MS.

Phase 3 THRIVE-AA2 data show deuruxolitinib in alopecia areata boosts hair regrowth and satisfaction in severe AA, with manageable safety, vs placebo.

Data from the STEPIn trial shows early intervention for plaque psoriasis with secukinumab delivers durable disease control, with some staying clear up to a year post treatment.

Psoriasis and macrophage research spotlights M1/M2 imbalance, interleukin therapies, and single-cell insights pointing to new precision targets.

New evidence links alopecia areata and atopic dermatitis overlap, revealing eczema-like immune signatures and dual-use JAK/OX40 therapies to watch.